US Patent 11,389,511: Scope, Claim Breadth, and U.S. Patent Landscape
US Patent 11,389,511 is directed to a subcutaneous, controlled-release CNP (C-type natriuretic peptide) agonist formulation and methods of treating CNP-amenable diseases. The core novelty in claim scope is a specific CNP peptide (SEQ ID NO:1-95; with a key disulfide ring architecture defined by cysteines corresponding to positions 22 and 38 of SEQ ID NO:24) combined with a polymer conjugate via a defined cleavable linker that is intended to reduce or eliminate side effects seen with free D-H under matched exposure, plus duration and dose parameters that support long subcutaneous dosing intervals.
What does the patent claim cover (independent claim 1 scope)?
1) Product category
Claim 1 is a pharmaceutical composition formulated for subcutaneous administration comprising a controlled-release CNP agonist.
2) Active: controlled-release CNP agonist defined at three levels
(a) Peptide identity and sequence constraints
- The CNP moiety has an amino acid sequence selected from SEQ ID NOS:1-95.
- It must include disulfide-bonded cysteines positioned so that the disulfides enclose a ring moiety.
- The ring architecture is defined by cysteine positions that correspond to positions 22 and 38 of SEQ ID NO:24.
(b) Defined functional architecture
- The claim requires a CNP moiety conjugated to a polymer via a cleavable linker.
- The linker enables controlled release of the CNP moiety after subcutaneous administration.
(c) Conjugation and carrier solubility bifurcation
Claim 1 is explicitly drafted around two platform variants:
- Water-soluble polymer conjugate: polymer is water-soluble and conjugated via the linker to the ring moiety; or
- Water-insoluble polymer conjugate: polymer is water-insoluble and conjugated via the linker to the ring moiety.
3) Side-effect reduction is a functional claim element
Claim 1 requires that after subcutaneous dosing:
- “a reduction or elimination of one or more side-effects is obtained compared to the subcutaneous administration of free D-H in an equivalent dosage.”
This is not framed as a comparative assay-only limitation; it is a required outcome tied to the formulation, which constrains infringement to formulations that replicate the comparative benefit.
4) Linker identity is extremely specific (formula II)
Claim 1 hardwires the linker as:
- “-L1- of formula (II)”
with a complex structural definition including:
- Attachment via amide bond to a lysine amine side chain of the CNP moiety.
- Multiple allowed connection motifs (e.g., -X- definitions; variable heteroatoms and carbonyl/sulfone/thiourea-like options appear in the variable sections).
- A constrained substitution set for R-groups:
- R groups can be H or C1-6 alkyl
- R3/R3a are H or C1-6 alkyl, with a condition that if non-H they connect through a sp3-hybridized carbon to the attached nitrogen.
- A ring (A) is limited to selected aromatic or cyclic systems including phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl.
- Optional intramolecular bonding options (pairs that can form additional ring closure).
- A second substituent framework:
- -Ll- is substituted with -L2-Z or -L2-Z′
- -Ll- optionally further substituted
- The claim includes a conditional restriction that asterisk-marked hydrogen in formula (II) cannot be replaced by -L2-Z or -L2-Z′ or substituted.
Conceptually: claim 1 ties protection tightly to a particular cleavable linker family that includes a carrier moiety element (-Z for water-soluble; -Z′ for water-insoluble).
5) Dose and exposure are pushed into dependent claims
While claim 1 does not fix dosing, the specification of:
- minimum concentration thresholds (nmol/mL)
- minimum unit dose and duration (nmol/kg; 24/48/168 hours)
appears throughout dependent claims 3, 7-11, 15-16, enabling enforceable product positioning around long-interval dosing.
How broad is the claim set versus a competitor’s alternative linker/polymers?
Breadth drivers
- The peptide identity is broad across SEQ ID NO:1-95 while still anchored to a specific disulfide ring motif.
- Polymer is allowed to be either water-soluble or water-insoluble, widening platform applicability.
- The linker formula (II) includes a wide set of allowable variables (R-group permutations; ring choice A set) that can cover many substituted analogs.
Breadth limits
- The linker must match formula (II) (and substitution constraints about the asterisk hydrogen).
- The peptide must satisfy the ring enclosed by disulfide-bonded cysteines corresponding to positions 22 and 38 of SEQ ID NO:24.
- Infringement includes a functional side-effect reduction comparison against free D-H at equivalent dosage.
- Dependent method claims restrict dosing duration and disease list, narrowing method use beyond generic CNP agonism.
Net: claim 1 is broad across peptide selection and polymer solubility, but constrained by linker structural formula and side-effect comparative requirement, which are common weak points for proving infringement against substantially different chemistries.
What is explicitly claimed in dependent claims (2-16)?
Cardiovascular side effect target (Claim 2)
- Side effects are cardiovascular side-effects.
This narrows the functional side-effect element for enforceability.
Minimum concentration requirements
- Claim 3: at least 25 nmol/mL of -D.
- Claim 7: at least 100 nmol/mL of -D.
These support product-specific dose strength and reduce “empty infringement” arguments where formulation claims are met but at lower concentration.
Peptide specificity variant (Claim 4)
This is a concrete “anchor” within the broader SEQ ID set.
Method of treatment base (Claims 5 and onward)
- Claim 5: subcutaneous administration of claim 1 composition to treat a disease that can be treated with a CNP agonist.
Hypotension reduction (Claim 6)
- Hypotension is reduced vs subcutaneous free D-H at equivalent dosage.
This is a more specific functional side-effect anchor.
Dosing amount and interval
- Claim 8: dose at least 50 nmol/kg of -D.
- Claim 9: dose at least 100 nmol/kg of -D.
- Claim 10: one unit dose provides effective amount for at least 48 hours.
- Claim 11: one unit dose provides effective amount for at least 168 hours.
- Claim 15: method at least 2 nmol/kg of -D.
- Claim 16: unit dose provides effective amount for at least 24 hours.
This creates a ladder of enforceable dosing intervals (24, 48, 168 hours) that track long-acting delivery positioning.
Disease scope (Claims 12-14): large osteochondrodysplasia and growth disorders list
Claim 12 lists an extensive set of diseases including:
- Achondroplasia
- Hypochondroplasia
- Short stature / dwarfism
- Multiple osteochondrodysplasias (including thanatophoric dysplasia, osteogenesis imperfecta variants, achondrogenesis, etc.)
- A mixed list that also includes neurofibromatosis type 1, LEOPARD syndrome, Noonan syndrome, SHOX deficiency, idiopathic short stature, and others
- Marfan syndrome, McCune-Albright syndrome
- Skeletal and growth-related syndromic conditions
Claim 13 narrows to achondroplasia.
Claim 14 narrows to selected group including:
- achondroplasia, hypochondroplasia, short stature, Noonan syndrome, SHOX deficiency
This disease list can be used to argue direct method infringement for the same patient population where CNP agonists are clinically positioned.
Claim-to-competitor mapping: where infringement is most likely to succeed
| Claim constraint |
What it forces in a competing product |
Infringement likelihood vs alternatives |
| CNP moiety ring disulfide architecture (cys positions corresponding to 22 and 38 of SEQ ID NO:24) |
Use of a CNP agonist peptide with the required disulfide ring geometry |
High only if peptide matches that architecture; changes to cysteine pairing or ring closure can avoid |
| Cleavable linker must be formula (II) (-L1-) with defined substitution rules |
Polymer conjugate chemistry must fall within formula II |
Low if competitor uses a different linker scaffold (even with similar functional performance) |
| Lysine attachment via amide bond |
Conjugation chemistry must connect the linker to lysine side chain |
Avoidable with alternative conjugation sites or non-lysine coupling |
| Side-effect reduction vs free D-H at equivalent dosage |
Comparative benefit needs to be demonstrable in the claim’s defined context |
Often litigated; could be hard to prove if comparator dosing differs or endpoint differs |
| Water-soluble vs water-insoluble polymer allowed |
Platform uses either solubility regime |
Increases breadth; does not protect if linker and peptide constraints are missed |
| Concentration and dosing interval thresholds (dependent claims) |
Formulation and regimen must hit minimum nmol/mL or nmol/kg and duration |
Competitors can avoid some dependent claims by reducing concentration or dosing interval, though independent claim 1 remains |
Patent landscape implications in the U.S. (what this patent blocks and what it leaves open)
Because this analysis is constrained to the information provided (claims text only), the landscape below is limited to scope-based risk areas typically covered by related U.S. filings in the same family and by typical design-around routes. It focuses on what is likely already structurally captured by this claim and what is likely still open to alternative chemistries.
Likely covered design space
This patent’s claim 1 structure targets:
- CNP peptide-polymer conjugates with controlled release
- Disulfide ring architecture in the peptide
- Specific cleavable linker chemistry with carrier substituents that map to water-soluble or water-insoluble polymer systems
- Subcutaneous long-acting dosing regimens (via dependent duration claims)
- Clinical use in osteochondrodysplasia and short stature syndromes (via dependent method claims)
Likely design-around levers
A competitor seeking to reduce U.S. infringement risk would focus on:
- Replacing the linker so it is not formula (II)
- Using a CNP agonist that does not meet the specific disulfide cysteine ring correspondence to positions 22 and 38 of SEQ ID NO:24
- Avoiding lysine-amide attachment configuration to the peptide
- Structuring comparative claims around side-effect endpoints that do not map cleanly to “reduction or elimination” as drafted (not a guarantee, but a litigation pressure point)
- Avoiding the dosing interval and minimum unit dose thresholds to defeat dependent method claims (while still facing claim 1)
Practical enforceability notes for freedom-to-operate
1) The functional side-effect comparison increases factual burden
Claims 1 and 6 depend on demonstrating:
- reduced cardiovascular side effects (claim 2)
- reduced hypotension (claim 6)
- compared to subcutaneous free D-H at equivalent dosage
This can create a litigation hinge: the defendant can attack comparability (equivalent dosage definition, patient variability, endpoint definitions), but the plaintiff has a built-in claim hook that ties chemistry to clinical tolerability.
2) Linker formula is the strongest structural gate
If a competitor linker is outside formula II, the patent’s structural limitation likely becomes dispositive for many composition claims.
3) Concentration and nmol/kg constraints support regimen-specific enforcement
Even if composition claims are contested, dependent claims 3, 7, 8-11, 15-16 provide additional hooks that can align with label-like dosing regimens, particularly for long interval products.
Key Takeaways
- US 11,389,511 protects a subcutaneous controlled-release CNP agonist built from a specific disulfide ring peptide architecture (cysteines corresponding to positions 22 and 38 of SEQ ID NO:24) plus a defined cleavable linker (-L1- formula II) that attaches to a lysine side chain via an amide bond.
- Claim scope is broad on peptide selection (SEQ ID NO:1-95) and polymer solubility (water-soluble or water-insoluble), but narrow on linker structure and disulfide ring geometry.
- Enforceability is strengthened by dependent claims that lock in dose strength (nmol/mL), unit dose (nmol/kg), and duration (24/48/168 hours) and a large method-of-use disease list focused on growth and osteochondrodysplasia indications.
- The functional element of side-effect reduction vs free D-H (notably cardiovascular effects and hypotension) creates a comparative clinical hook that can be decisive if comparator dosing and endpoints align in litigation.
FAQs
1) What is the primary commercial “product form” covered by US 11,389,511?
A subcutaneous controlled-release polymer conjugate of a CNP agonist peptide with a specific disulfide ring motif, released via a cleavable linker defined by formula (II).
2) What peptide feature is mandatory even though SEQ ID NOS:1-95 are permitted?
The peptide must have disulfide-bonded cysteines that enclose a ring moiety, with cysteines corresponding to positions 22 and 38 of SEQ ID NO:24.
3) Does the patent cover both water-soluble and water-insoluble polymer systems?
Yes. Claim 1 covers a composition where the polymer is water-soluble or water-insoluble, with conjugation occurring through the defined linker to the ring moiety.
4) Which dependent claims are most useful for enforcing a dosing regimen?
Claims 8-11 and 15-16: dosing thresholds (>=50 or >=100 nmol/kg, or >=2 nmol/kg) and duration windows (>=24, >=48, >=168 hours) are directly recited.
5) What disease areas are covered for method-of-use claims?
A wide set of CNP-treatable growth, short stature, and osteochondrodysplasia conditions, including achondroplasia, hypochondroplasia, SHOX deficiency, Noonan syndrome, and multiple osteochondrodysplasias, plus syndromic disorders listed in claim 12.
References
No external sources were provided in the prompt, and no patent-text citation base beyond the claim text itself is available here.
